The rat brain-derived neurotropic factor (BDNF) gene consists of four S' exons lnked to separate promoters and one 3' exon encoding the prepro-BDNF protein.
Brain-derived neurotrophic factor (BDNF; refs. 1 and 2) is a member of the neurotrophin family, which also includes nerve growth factor (NGF) (3), neurotrophin-3 (NT-3) (4-9), and neurotrophin 4/5 (NT-4) (10) (11) (12) . BDNF promotes the survival of retinal ganglion cells (13) , basal forebrain cholinergic neurons (14) , and embryonic mesencephalic dopaminergic neurons (15, 16) in cell culture. In vivo BDNF has been shown to increase the survival of embryonic sensory neurons (17) and developing as well as injured motoneurons (18) (19) (20) .
BDNF mRNA is expressed in neurons throughout the brain with the highest level in the hippocampus (8, (21) (22) (23) (24) . The findings that the glutamate analog kainic acid (KA) and the 'y-aminobutyric acid subtype A (GABAA) receptor antagonist bicuculline increase BDNF mRNA levels in hippocampal neurons have led to the hypothesis that the balance between the activity of the GABAergic and glutamatergic systems controls the level of BDNF mRNA in the hippocampus (25) (26) (27) (28) . Moreover, stimulation of the septohippocampal pathway transiently increases BDNF mRNA in the hippocampus (29) . Similarly, seizure activity induced by focal electrolytic lesions (30) or repeated subconvulsive
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electrical stimulations (31) in the hippocampus lead to marked and transient increases of BDNF mRNA in the dentate gyrus, neocortex, and piriform cortex.
The increase of BDNF mRNA following KA treatment has been suggested to be due to a glutamate receptor activation. The glutamate receptor family has been classified into two main groups: the metabotropic receptors, which exert longlasting actions through the modulation of intracellular signals, and the ionotropic receptors, which contain glutamategated cation channels providing fast synaptic responses (32) . lonotropic receptors, further subdivided according to pharmacological criteria into N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) low-affinity kainate receptor, and high-affinity kainate receptors, have been implicated in the increase of BDNF mRNA after treatment with KA (25, 26) and after electrical stimulations (31) .
The recent molecular cloning of the rat BDNF gene has revealed a complex gene structure with four short 5 Abbreviations: NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; NT-3, neurotrophin 3; NT-4, neurotrophin 4; NMDA, N-methyl-D-aspartate; AMPA, a-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid; GABA, 't-aminobutyric acid; KA, kainic acid; NBQX, 2,3-dihydroxy-6nitrosulfanoylbenzo(f)quinoxaline; CNQX, 6-cyano-7-nitroquinoxaline-2,3-dione.
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tDeceased May 16, 1993. RNA Preparation and Northern Blot Analysis. Total and poly(A) RNA from the indicated tissues were purified and analyzed by Northern blot as described (33) . The filters were hybridized to the following BDNF exon-specific probes: for exon I, a 0.35-kb Sac 1-HindIII genomic fragment; for exon II, a cDNA fragment covering the sequence 2067-2229 in the rat BDNF gene; for exon III, a cDNA fragment covering sequence 782-975 in the rat BDNF gene; and for exon IV, a cDNA fiagment covering sequence 1790-2056 in the rat BDNF gene (33) . The same filters were also rehybridized with a mouse P-actin cDNA probe to standardize for the amount of mRNA in each lane. Appropriate exposures of all autoradiograms were quantified using a Shimadzu CS-9000 densitometer. The levels ofthe different BDNF mRNAs were then normalized relative to the levels of actin mRNA.
In Situ Hybridization and Image Analysis. The same DNA fiagments as used for the Northern blots were used to synthesize UTP[a-35S]-labeled complementary RNA probes. Coronal sections (14 um) from fresh frozen adult SpraqueDawley rat brain were analyzed by in situ hybridization as described (33) . To quantify the relative levels of the different BDNF transcripts in control and treated brains, the optical density values of the autoradiograms were measured using a Quantimet 570 image processing and analysis system (Cambridge Instruments, Cambridge, U.K.). For calibration, an autoradiographic microscale (Amersham) was coexposed on all x-ray films. The number of neurons per unit area in the different brain regions was determined by counting on cresyl violet-stained sections. The optical density values were divided by the neuron density, thus providing an estimate of the labeling intensity over individual neurons in the areas measured. All measurements were performed on at least six different tissue specimens. An overall statistical test using ANOVA was used to determine the significance of differences among the various groups of animals.
RESULTS
Levels of Exon-Spedfic BDNF mRNAs After Treatments with KA. BDNF exon I mRNA increased 50-fold in the hippocampus 3 hr after a systemic injection of KA (Fig. 1) . The level was the same at 4.5 hr but tapered off to 10-fold higher than control 6 hr after the injection. A 10-fold increase was seen in the cerebral cortex at 3 hr, which remained at the same level at the later time points. Exon II mRNA increased 5-fold in hippocampus at 3 hr, declined at 4.5 hr and reached 3-fold higher than control at 6 hr ( Fig. 1) . Only low levels of exon II mRNA were detected in the cerebral cortex with 3-fold higher levels than control at all time points after the KA injection. Exon III mRNA showed similar increases in hippocampus and cerebral cortex, with 20-fold higher levels at 3 hr declining to 10-and 3-fold more than control at 4.5 and 6 hr, respectively. In hippocampus and cerebral cortex, exon IV mRNA increased 2-fold 3 hr after the KA injection and returned to control levels at 6 hr. RNase protection assays showed that in hippocampus and cerebral cortex the same major initiation sites (cap sites) were used for exon I, II, and III mRNAs in control animals and in animals analyzed 3 hr after KA treatment, whereas for exon IV mRNA the KA treatment induced a cluster of cap sites not seen in the control located 218-222 bp upstream of the 3' end of exon IV (data not shown).
Exon-Speciflc BDNF mRNA Analyzed by In Situ Hybridization. In situ hybridization revealed a more pronounced increase of exon I mRNA than exon H mRNA after the treatment with KA, although the regional distribution of the increases was similar for the two exons (Fig. 2 B and G) . The highest increases were seen in the granular cell layer of the dentate gyrus, pyramidal cell layers of the neocortex and piriform cortex, dorsal endopiriform nuclei, and lateral and dorsolateral amygdaloid nuclei. Less pronounced increases hybridized to the indicated BDNF exon-specific probes. The same filter was used for all probes. The filter was also hybridized with a probe for 3-actin to standardize for the amount of mRNA in each lane. The filter was washed at high stringency followed by exposure to x-ray film.
were seefh in the pyramidal layers of the hippocampus, posterior paraventricular thalamic nuclei, and ventromedial hypothalamic nuclei. (Figs. 2H and 4) .
Following KA treatment, exon III mRNA increased markedly in the granular layer of the dentate gyrus, the CAl and CA2 regions of the hippocampus, neocortex, and piriform cortex and the lateral amygdaloid complex (Fig. 2L) . A moderate increase was seen in the CA3 region of the hippocampus, the internal pyramidal layer of neocortex, medial amygdaloid nuclei, ventral paraventricular thalamic nuclei, and ventromedial hypothalamic nuclei. MK801 reduced the increase of exon III mRNA in neocortex and piriform cortex by 80 and 50%6, respectively (Figs. 2M and 4) . Similarly, NBQX reduced the increase in neocortex and piriform cortex by 70% and 50%6, respectively (Figs. 2N and 3) . The increase in the CA3 region and dentate gyrus was not blocked by MK801 or NBQX, whereas both antagonists reduced the increase in CAl region by =5096 (Fig. 3) . The KA treatment induced a modest increase in exon IV mRNA, predominantly in the hippocampus and neocortex. This increase was not blocked by MK801 or NBQX (Fig. 2 R and S) .
Three hours after a systemic injection of bicuculline, exon I and III mRNAs increased 15-and 5-fold, respectively in the granule cell layer of the dentate gyrus (Fig. 2 E and 0) . A modest increase was also seen for exon I and III mRNAs in the neocortex and piriform cortex. In contrast, no change or only small changes were seen for exon II and IV mRNAs in these brain regions (Fig. 2 J and T) .
Three hours after a systemic injection of the muscarinic receptor agonist pilocarpine, exon I mRNA increased markedly in neurons of layer VI of the parietal cortex (compare Fig. 4 A and C) . A modest increase was also seen in neurons of layer V, whereas no change was seen in the other brain regions examined. The pilocarpine treatment had no significant effect on exon II, III, and IV mRNAs.
DISCUSSION
In this study we have used BDNF exon-specific probes to demonstrate that BDNF mRNAs containing different 5' exons are differentially expressed in the adult rat brain. A separate promoter is present upstream of each of the four 5' exons as revealed by transfection of promoter-reporter gene constructs in cell culture (33) and by the expression of these constructs in transgenic mice (unpublished data). It is therefore likely that the changes in exon-specific mRNAs reported here are due to a differential activation of the four different BDNF promoters. All exon-specific BDNF transcripts contain the coding sequence for the prepro-BDNF protein, although sequences within the untranslated 5' exons could form secondary structures that may affect their translatability (33) . Analysis of BDNF exon-specific sequences in polysomal RNA from hippocampus and cerebral cortex of normal and KA-treated rats showed that all BDNF exon-specific mRNAs are associated with polysomes (data not shown). This implies that all BDNF exon-specific mRNAs are used for translation of the prepro-BDNF protein.
Treatment with the GABAA receptor antagonist bicuculline increases BDNF mRNA in hippocampal neurons (26) . Our results provide evidence that this increase is mediated by a selective activation of BDNF promoters I and III and is mostly restricted to the dentate gyrus, a structure highly enriched in GABAergic nerve terminals and GABA receptors. A marked exon-specific response was also found after treatment with the muscarinic receptor agonist pilocarpine, which caused a significant increase of exon I mRNA in the parietal cortex. The regional restriction in the response to pilocarpine indicates that only a subset of muscarinic receptors regulates the expression of BDNF exon I mRNA.
Previous studies using probes from the protein coding part of the BDNF gene (exon V), detecting a pool of all BDNF exon mRNAs, have revealed marked increases of BDNF mRNA after treatment with KA (25) (26) (27) (28) Fig. 2 . The regions analyzed are indicated. The number of neurons per unit area was calculated for each region and the optical density values were divided with the neuronal density. Thus the bars represent a measure of the relative labeling intensity over individual neurons in different brain areas. The level of exon III mRNA in the CAl region after KA treatment was arbitrarily set at 100. Six measurements were made for each probe and brain area and the results shown are the mean values ± standard deviation. Asterisks indicate significant effects of pretreating the animals with glutamate receptor antagonists compared to KA alone (P < 0.05 using ANOVA). Abbreviations as in Fig. 2. The position of the cap sites for exon I, II, and III mRNAs was the same in control and KA-treated animals, suggesting that the structure and the translatability of these mRNAs were not changed after the KA treatment. However, for exon IV a new major cap site was induced by KA and this shift removes part of the 5' end of exon IV mRNA, which may improve the translatability ofthis mRNA (33) . Thus, for exon IV mRNA, transcriptional and translational changes may control the amount of prepro-BDNF protein synthesized after KA treatment.
In addition to the direct activation ofkainate receptors, KA causes a release of glutamate in the brain and this has been suggested to mediate the increase of BDNF mRNA (25) . The different regional distributions in the response comparing the four exons could be due to the fact that the BDNF promoters are differentially induced following activation of various subsets ofglutamate receptors. The results obtained by the use of specific glutamate receptor antagonists revealed two main patterns of region-specific, glutamate receptor-mediated regulation of exon-specific BDNF mRNAs.
The first pattern was seen in the neocortex, piriform cortex, and amygdaloid complex, where the increases of exon I, 1, and III mRNAs were partially blocked by MK801 and NBQX. This suggests that NMDA and AMPA/kainate receptors are involved in the regulation of promoters I, II, and Ill in these brain regions. The only exception was the increase of exon I in the piriform cortex, which was blocked only by NBQX, indicating that NMDA receptors are not involved. The finding that NMDA and AMPA/kainate receptors are involved in the KA induction of exon-specific BDNF mRNA suggests that (i) polysynaptic pathways using different glutamate receptors are involved or (ii) presynaptic kainate receptors stimulated by KA induce glutamate release and activate postsynaptic glutamate receptors in a similar fashion to that described in the hippocampus (34, 35) . Correlation of the glutamate receptor subtype distribution in the piriform cortex and amygdaloid complex (36) (37) (38) (39) and the blockade of the kainate response by NBQX suggest that the kainate effect might be triggered by either homodimeric GluR5Q (unedited) or heterodimeric KA2/GluR6 or KA2/ GluRS receptors. The increases of exons I, II, and III in neocortex may be due to an activation of heterodimeric GluR6/KA receptors that are sensitive to 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and mainly localized in cortical layers II and IV (37, 38, 40) . In addition, glutamate receptor subunits 1, 2, and 3 forming AMPA low-affinity kainate receptors (41) (42) (43) (1993) intriguing since it has recently been shown (37) that the glutamate receptor subunit GluR6 is enriched in the dentate gyrus and CA3 region and forms homodimeric, CNQX lowsensitivity, high-affinity kainate receptors. Although we cannot rule out the involvement of metabotropic receptors due to the lack of selective antagonists, our data suggest that the KA-mediated increases of exon I and III mRNAs in the hippocampus may occur through the GluR6 subtype of kainate receptors.
Exceptions to the pattern ofregulation in the hippocampus were seen in the dentate gyrus, where the increase of exon I mRNA was blocked by NBQX, and in the CAl region, where the increase of exon III mRNA was blocked by MK801 and NBQX. This suggests that NMDA receptors are not regulating exon I mRNA in the dentate gyrus, whereas NMDA and AMPA/kainate receptors could be involved in the increase of exon III mRNA in the CAl region. In this case, in addition to a postsynaptic activation of AMPA/kainate receptors, presynaptic kainate receptors (34) could induce glutamate release from hippocampal mossy fibers (35) and activate postsynaptic NMDA receptors. Given that in both cases the kainate action could be blocked by NBQX, it may be possible that either the heterodimeric AMPA high-affinity kainate receptor GluR6/KA2 (38) or AMPA low-affitnity kainate receptors formed by subunit 1, 2, 3, or 4 (41, 43, 46) may be involved since they are sensitive to CNQX and expressed in the CAl region and dentate gyrus.
Since all treatments in this study were applied systemically, we cannot rule out more complex indirect pathways leading to the differential activation of BDNF promoters. However, the significant correlation of these effects with glutamate receptor subtype distribution leads us to suggest that some particular combination of glutamate receptor subunits, if functional in that particular region, may be responsible for the specific induction of the different BDNF promoters.
The regional variations in the brain in the expression of the four BDNF 5' exon mRNAs in response to changes in neuronal activation suggest that the four transcription units within the BDNF gene are independently regulated. The blocking effects of glutamate receptor antagonists on BDNF exon-specific mRNAs suggest that a broad spectrum of different glutamate receptors regulates, in a precise manner, the expression of BDNF mRNA in different brain areas. The functional consequence of this regulation is not known, but the fact that the treatments used in this study enhance memory, at low doses, or induce seizures, at high doses (45, 47, 48) , suggests that BDNF may provide a trophic feedback to the afferent nerve terminals, which results in a reinforcement of these inputs.
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